News

Nasoni Takes the Lead in Transforming Care for Alzheimer’s and Dementia Patients with $2.4M Federal Grant

Hampton Roads stands at the forefront of innovation by announcing a $2.4 million federal grant to enhance care for Alzheimer’s and dementia patients. This funding, spearheaded by Congresswoman Jen Kiggans, not only highlights the region’s commitment to healthcare but also emphasizes the role of local startups like Nasoni, which are driving the future of patient care.

Nasoni, a forward-thinking Hampton Roads startup known for its innovative faucet designs, is expanding its reach into healthcare with solutions that improve the quality of life for patients facing cognitive challenges. As part of the broader effort supported by the federal grant, Nasoni will play a crucial role in developing practical, user-friendly technologies to assist patients and caregivers alike.

Their patented faucets, designed with ease of use in mind, are particularly valuable for individuals with Alzheimer’s and dementia. With simple features that allow for better access to clean water, Nasoni’s faucets reduce daily stress and improve hydration—an often overlooked but critical aspect of care for aging populations.

Founder Steve Waddell is optimistic about Nasoni’s impact. “Our goal has always been to make life easier through innovative design,” Waddell says. With this grant, we can extend that mission to vulnerable populations in Hampton Roads, providing practical solutions that ease the burdens of care.”

Kiggans, a former geriatric nurse practitioner, recognizes the importance of such local innovations. “Companies like Nasoni are key to revolutionizing the way we support Alzheimer’s and dementia patients. Their commitment to improving everyday tasks like access to clean water aligns with our goal of enhancing patient care in meaningful ways,” she shared during the announcement.

In addition to Nasoni’s contributions, the grant will fund various community-based programs, caregiver training, and healthcare initiatives designed to enhance early detection and personalized care strategies. By combining Nasoni’s innovative products with these expanded services, Hampton Roads is set to become a model for Alzheimer’s and dementia care.

The collaboration between local businesses and healthcare providers underscores the region’s thriving ecosystem of startups and technology. As Nasoni continues to expand its influence, its work will serve as a shining example of how ingenuity can positively impact patient care on a large scale.

This grant not only advances the fight against Alzheimer’s and dementia but also highlights the role of Hampton Roads startups in solving critical healthcare challenges. With Nasoni’s help, the future of care in the region looks brighter than ever.

 

Read more here.

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation